HALOZYME THERAPEUTICS, INC. business relationships
Companies named in HALOZYME THERAPEUTICS, INC.’s 10-K filed 2026-02-17, and public companies whose annual reports name HALOZYME THERAPEUTICS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 92 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in HALOZYME THERAPEUTICS, INC.’s annual report 10
“We receive royalties for Phesgo sales in Japan as part of our licensing agreement with Roche.” SEC filing
“We currently earn royalties from the sales of ten commercial products including sales of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.” SEC filing
“We currently earn royalties from the sales of ten commercial products including sales of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.” SEC filing
“In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics.” SEC filing
“In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics.” SEC filing
“In September 2023, we provided Lipocine notice of termination of the TLANDO license agreement effective January 31, 2024.” SEC filing
“• Phillips-Medisize Corporation, an international outsource provider of design and manufacturing services, produces commercial quantities of components of our QuickShot auto-injector device for XYOSTED and other partnered products and our VIBEX epinephrine auto-injector product with Teva.” SEC filing
“In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics.” SEC filing
“In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics.” SEC filing
“We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. ("Avid"), Catalent Indiana LLC ("Catalent") and Lonza Sales AG ("Lonza") to produce supplies of bulk rHuPH20.” SEC filing
Companies whose annual reports name HALOZYME THERAPEUTICS, INC. 3
“In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics,” SEC filing
“In November 2023, we announced a global collaboration and license agreement with Halozyme, Inc., or Halozyme, to develop a subcutaneous formulation of sabirnetug.” SEC filing
“On December 18, 2025, the Company entered into a Non-exclusive Collaboration and License Agreement (the "Halozyme License Agreement") with Halozyme, Inc. ("Halozyme").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.